David Lebowitz
Stock Analyst at Citigroup
(2.40)
# 2,388
Out of 4,843 analysts
111
Total ratings
46.84%
Success rate
-1.59%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Maintains: Buy | $45 → $56 | $43.04 | +30.11% | 3 | May 15, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $14 → $10 | $6.87 | +45.56% | 8 | May 9, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $86 → $80 | $31.02 | +157.90% | 2 | May 7, 2025 | |
| PLRX Pliant Therapeutics | Maintains: Neutral | $4 → $1.5 | $1.35 | +11.11% | 6 | Mar 4, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $45 → $49 | $34.25 | +43.07% | 3 | Feb 21, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $67 → $64 | $33.51 | +90.99% | 12 | Feb 20, 2025 | |
| PTCT PTC Therapeutics | Maintains: Sell | $32 → $45 | $48.52 | -7.25% | 4 | Feb 12, 2025 | |
| INCY Incyte | Maintains: Buy | $97 → $88 | $65.06 | +35.26% | 5 | Feb 11, 2025 | |
| VKTX Viking Therapeutics | Initiates: Neutral | $38 | $26.80 | +41.79% | 1 | Feb 7, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $65 → $68 | $44.42 | +53.08% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $19.78 | +253.89% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $5.44 | +175.74% | 3 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $207 | $162.73 | +27.20% | 12 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $65 → $76 | $101.35 | -25.01% | 5 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $37 | $21.62 | +71.14% | 9 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $275.26 | +38.78% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $58.07 | +65.32% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $1.71 | +601.75% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $304.56 | -46.15% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $13.04 | +199.08% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $10.54 | +99.24% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $4.20 | +9,542.86% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $0.60 | +2,236.84% | 2 | Oct 12, 2021 |
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45 → $56
Current: $43.04
Upside: +30.11%
Intellia Therapeutics
May 9, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $6.87
Upside: +45.56%
Cytokinetics
May 7, 2025
Maintains: Buy
Price Target: $86 → $80
Current: $31.02
Upside: +157.90%
Pliant Therapeutics
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.35
Upside: +11.11%
BridgeBio Pharma
Feb 21, 2025
Maintains: Buy
Price Target: $45 → $49
Current: $34.25
Upside: +43.07%
Ionis Pharmaceuticals
Feb 20, 2025
Maintains: Buy
Price Target: $67 → $64
Current: $33.51
Upside: +90.99%
PTC Therapeutics
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $48.52
Upside: -7.25%
Incyte
Feb 11, 2025
Maintains: Buy
Price Target: $97 → $88
Current: $65.06
Upside: +35.26%
Viking Therapeutics
Feb 7, 2025
Initiates: Neutral
Price Target: $38
Current: $26.80
Upside: +41.79%
Mirum Pharmaceuticals
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $44.42
Upside: +53.08%
Oct 7, 2024
Initiates: Buy
Price Target: $70
Current: $19.78
Upside: +253.89%
Sep 24, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $5.44
Upside: +175.74%
Sep 17, 2024
Maintains: Buy
Price Target: $178 → $207
Current: $162.73
Upside: +27.20%
May 3, 2024
Maintains: Sell
Price Target: $65 → $76
Current: $101.35
Upside: -25.01%
May 2, 2024
Maintains: Buy
Price Target: $39 → $37
Current: $21.62
Upside: +71.14%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $275.26
Upside: +38.78%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $58.07
Upside: +65.32%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $1.71
Upside: +601.75%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $304.56
Upside: -46.15%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $13.04
Upside: +199.08%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $10.54
Upside: +99.24%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $4.20
Upside: +9,542.86%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $0.60
Upside: +2,236.84%